|
CD73
|
|
Negatively prognostic
|
NSCLC (stage I-III)
|
High CD73 expression was an independent risk factor for decreased overall survival and dereased recurrence-free survival
|
642
|
Inoue, et al. [54]
|
|
Prostate Cancer
|
CD73 expression in normal tissue was a negative prognostic factor for prostate-infiltrating CD8(+) cells. However, high expression of CD73 in tumor stroma was associated with longer recurrence-free survival
|
285
|
Leclerc, et al. [55]
|
|
Breast Cancer (Triple Negative)
|
CD73 expression is associated with anthracycline resistance and poor prognosis
|
6000
|
Loi, et al. [56]
|
|
High-Grade Serous Ovarian Cancer
|
High levels of CD73 are associated with shorter disease-free survival and overall survival
|
1581
|
Gaudreau, et al. [57]
|
|
Colorectal Cancer (stage I-IV)
|
High expression of CD73 predicts poor survival
|
223
|
Wu, et al. [58]
|
|
Gastric Cancer (stage I-IV)
|
High expression CD73 is associated with lowered overall survival
|
68
|
Lu, et al. [65]
|
|
Melanoma (Stage IV)
|
High soluble CD73 activity was associated with poor overall survival and poor progression-free survival
|
37
|
Morello, et al. [59]
|
|
Head and Neck Cancer (stage I-IV)
|
High levels of CD73 are associated with reduced overall survival
|
162
|
Ren, et al. [60]
|
|
Renal Cell Cancer (Stage I-IV)
|
High expression of CD73 is associated with disease progression and shortened overall survival
|
189
|
Yu, et al. [2]
|
|
Positively prognostic
|
Nonmuscle-Invasive Urothelial Bladder Cancer
|
High CD73 iactivity was associated with favorable clinicopathological features. Furthermore, predicts better outcome in the subgroup of pTa and pT1 tumors.
|
174
|
Wettstein, et al. [61]
|
|
Breast Cancer (stage I-III)
|
CD73 expression strongly correlated with longer disease-free survival and overall survival
|
136
|
Supernat, et al. [62]
|
|
Endometrial Carcinoma (endometrial endometrioid carcinomas, Grade 1–3) and nonendometrioid uterine papillary serous carcinomas
|
CD73 is markedly downregulated in poorly differentiated and advanced-stage disease compared with levels in normal endometrium and low-grade tumors
|
49
|
Bowser, et al. [64]
|
|
Colorectal cancer (Stage IV)
|
High CD73 expression was associated with longer progression free survival from cetuximab treatment in patients with KRAS-WT and KRAS-mutant tumors
|
238
|
Cushman, et al. [63]
|
|
CD39
|
|
Negatively prognostic
|
Gastric Cancer (stage I-IV)
|
High CD39 expression is a predictor of poor outcome following radical resection
|
101
|
Cai, et al. [69]
|
|
Hepatocellular carcinoma
|
High CD39 expression is an independent indicator of decreased overall suvival after radical resection
|
324
|
Cai, et al. [70]
|
|
Chronic lymphocytic leukemia
|
CD39 expression on CD4+ lymphocytes are increased in the peripheral blood of patients with CLL and correlates with advanced stage of disease
|
62
|
Perry, et al. [71]
|
